ProShare Advisors
LYEL icon

ProShare Advisors’s Lyell Immunopharma LYEL Stock Holding History

ProShare Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,398
Closed -$25.8K – 2140
2025
Q1 		$25.8K Sell
2,398
-526
-18% -$6.44K ﹤0.01% 2018
2024
Q4 		$37.4K Buy
2,924
+649
+29% +$12.9K ﹤0.01% 2216
2024
Q3 		$62.8K Buy
2,275
+326
+17% +$9.58K ﹤0.01% 1951
2024
Q2 		$56.5K Sell
1,949
-500
-20% -$23.8K ﹤0.01% 1735
2024
Q1 		$109K Buy
2,449
+208
+9% +$8.91K ﹤0.01% 1808
2023
Q4 		$86.9K Buy
2,241
+293
+15% +$10.6K ﹤0.01% 1800
2023
Q3 		$57.3K Buy
1,948
+12
+0.6% +$570 ﹤0.01% 1701
2023
Q2 		$123K Buy
1,936
+52
+3% +$2.88K ﹤0.01% 1660
2023
Q1 		$88.9K Sell
1,884
-260
-12% -$13.9K ﹤0.01% 1609
2022
Q4 		$149K Buy
2,144
+148
+7% +$14.7K ﹤0.01% 1565
2022
Q3 		$293K Buy
1,996
+66
+3% +$8.94K ﹤0.01% 1170
2022
Q2 		$251K Sell
1,930
-707
-27% -$72.2K ﹤0.01% 1320
2022
Q1 		$267K Buy
2,637
+686
+35% +$83.1K ﹤0.01% 1706
2021
Q4 		$302K Buy
+1,951
New +$435K ﹤0.01% 1785

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ProShare Advisors's LYEL Position: Q2 2025 in Review

ProShare Advisors sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 2,398 shares — an estimated $25.8K sold.

ProShare Advisors first reported a position in LYEL in Q4 2021 and held it in 14 quarters. The position peaked at $302K in Q4 2021. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • ProShare Advisors reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 2,398 Lyell Immunopharma shares in Q2 2025, an estimated $25.8K.
  • ProShare Advisors first reported a position in Lyell Immunopharma in Q4 2021 and held it in 14 quarters.
  • ProShare Advisors's Lyell Immunopharma position peaked at $302K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.